HK1253516A1 - 14-3-3η抗體及其用於診斷和治療關節炎的用途 - Google Patents
14-3-3η抗體及其用於診斷和治療關節炎的用途Info
- Publication number
- HK1253516A1 HK1253516A1 HK18112716.8A HK18112716A HK1253516A1 HK 1253516 A1 HK1253516 A1 HK 1253516A1 HK 18112716 A HK18112716 A HK 18112716A HK 1253516 A1 HK1253516 A1 HK 1253516A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- arthritis
- diagnosis
- treatment
- eta antibodies
- eta
- Prior art date
Links
- 102000004899 14-3-3 Proteins Human genes 0.000 title 1
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 title 1
- 206010003246 arthritis Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001163—Phosphatases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99052007P | 2007-11-27 | 2007-11-27 | |
US7712308P | 2008-06-30 | 2008-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1253516A1 true HK1253516A1 (zh) | 2019-06-21 |
Family
ID=40677991
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11105914.9A HK1151728A1 (zh) | 2007-11-27 | 2011-06-10 | 用於預防和治療關節炎的 拮抗劑 |
HK18112716.8A HK1253516A1 (zh) | 2007-11-27 | 2018-10-05 | 14-3-3η抗體及其用於診斷和治療關節炎的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11105914.9A HK1151728A1 (zh) | 2007-11-27 | 2011-06-10 | 用於預防和治療關節炎的 拮抗劑 |
Country Status (11)
Country | Link |
---|---|
US (6) | US9079947B2 (zh) |
EP (4) | EP3192808A1 (zh) |
JP (5) | JP5781764B2 (zh) |
KR (5) | KR20170116184A (zh) |
CN (3) | CN101952313B (zh) |
AU (2) | AU2008329466B2 (zh) |
BR (2) | BRPI0819066A2 (zh) |
CA (2) | CA2706479C (zh) |
HK (2) | HK1151728A1 (zh) |
IL (3) | IL205907A0 (zh) |
WO (2) | WO2009067811A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2021792E (pt) | 2006-05-09 | 2013-05-23 | Univ British Columbia | Marcadores proteicos dissolvidos para artrite |
JP5781764B2 (ja) | 2007-11-27 | 2015-09-24 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 14−3−3η抗体、並びに関節炎の診断及び治療のためのその使用 |
KR101894597B1 (ko) * | 2009-03-11 | 2018-10-04 | 오거렉스 라이프 사이언시스 코포레이션 | 관절염 상태를 특성화하는 조성물 및 방법 |
US9474540B2 (en) | 2009-10-08 | 2016-10-25 | Ethicon-Endo-Surgery, Inc. | Laparoscopic device with compound angulation |
US9226760B2 (en) | 2010-05-07 | 2016-01-05 | Ethicon Endo-Surgery, Inc. | Laparoscopic devices with flexible actuation mechanisms |
US8562592B2 (en) | 2010-05-07 | 2013-10-22 | Ethicon Endo-Surgery, Inc. | Compound angle laparoscopic methods and devices |
GB201016494D0 (en) * | 2010-09-30 | 2010-11-17 | Queen Mary Innovation Ltd | Polypeptide |
EP2768851B1 (en) | 2011-10-21 | 2017-05-31 | Augurex Life Sciences Corporation | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
GB201200555D0 (en) * | 2012-01-13 | 2012-02-29 | Univ Birmingham | Peptide |
CN103060360A (zh) * | 2013-01-04 | 2013-04-24 | 昆明理工大学 | 黑大豆14-3-3j蛋白基因的原核表达载体及其应用 |
CN104099348B (zh) * | 2013-04-15 | 2017-03-29 | 上海市农业科学院 | 一种来源于耐高温菌的重金属结合蛋白基因及其抗重金属应用 |
CN103555750B (zh) * | 2013-05-17 | 2015-04-08 | 温州医科大学附属第二医院 | 一种人子宫肌瘤14-3-3 γ高表达载体的构建方法及应用 |
WO2014202178A1 (de) * | 2013-06-20 | 2014-12-24 | Merck Patent Gmbh | Verfahren zur steuerung der optischen eigenschaften von uv-filterschichten |
KR101489844B1 (ko) * | 2013-06-27 | 2015-02-06 | 강원대학교산학협력단 | 14-3-3 시그마 유전자 결손 마우스, 이를 이용한 인 비보 패혈증 연구모델 개발 방법 및 그 응용 |
WO2015031645A1 (en) * | 2013-08-28 | 2015-03-05 | Washington University | Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv |
AU2015330955A1 (en) * | 2014-10-08 | 2017-05-25 | Central Adelaide Local Health Network Inc. | Modulators of 14-3-3 functionality and uses thereof |
KR101946884B1 (ko) * | 2017-04-25 | 2019-02-13 | 고려대학교 산학협력단 | 대사체 분석을 이용한 베체트병의 진단방법 |
JP2019054181A (ja) * | 2017-09-19 | 2019-04-04 | 東芝メモリ株式会社 | 半導体パッケージ |
CN109596829A (zh) * | 2017-12-07 | 2019-04-09 | 南京医科大学 | 一种肝癌标志蛋白及其检测方法 |
JP7381086B2 (ja) * | 2017-12-21 | 2023-11-15 | リソリス バイオ, インコーポレイテッド | エーラス・ダンロス症候群の治療用組成物および治療法 |
CN110579600B (zh) * | 2018-05-23 | 2023-12-26 | 科美诊断技术股份有限公司 | 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法 |
CN110579597A (zh) * | 2018-05-23 | 2019-12-17 | 科美诊断技术股份有限公司 | 检测14-3-3 eta蛋白的非均相化学发光免疫检测试剂盒及其应用 |
CN110726843A (zh) * | 2018-07-16 | 2020-01-24 | 科美诊断技术股份有限公司 | 检测14-3-3eta蛋白的化学发光免疫检测试剂盒及其应用 |
WO2020102623A1 (en) * | 2018-11-15 | 2020-05-22 | The University Of Toledo | Materials and methods for the prevention of rheumatoid arthritis |
WO2020138674A1 (ko) * | 2018-12-26 | 2020-07-02 | (주)케어젠 | 근육 이완용 조성물 |
MX2020014330A (es) * | 2018-12-26 | 2021-03-09 | Caregen Co Ltd | Composicion para relajacion muscular. |
CN109593131B (zh) * | 2018-12-27 | 2021-09-03 | 南京医科大学 | 一种抗14-3-3η蛋白单克隆抗体及其用途 |
CN109897109B (zh) * | 2019-01-30 | 2022-09-09 | 常州市第二人民医院 | 抗肿瘤标志蛋白单克隆抗体及其用途 |
US11248325B2 (en) | 2019-11-19 | 2022-02-15 | Whirlpool Corporation | Laundry appliance having a processing belt |
CN111606977B (zh) * | 2020-05-27 | 2021-11-09 | 福建农林大学 | 一种利用GF14f蛋白靶向多肽配体调控水稻弱势籽粒灌浆的方法 |
CN114286684B (zh) * | 2020-07-27 | 2024-01-05 | 华中科技大学 | 与stat3相关的疾病的预防和/或治疗 |
CN117899196A (zh) * | 2024-03-18 | 2024-04-19 | 中国人民解放军总医院第一医学中心 | 14-3-3zeta蛋白或YWHAZ基因在角膜损伤治疗中的应用 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526714A (en) | 1982-12-13 | 1985-07-02 | Cordis Europa N.V. | Conjugates of anticoagulant and protein |
US4956281A (en) | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US6596476B1 (en) | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5359681A (en) | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5948765A (en) * | 1996-03-15 | 1999-09-07 | Washington University | Inhibition of intracellular signal transduction by 14-3-3-binding peptides |
US5998149A (en) | 1996-04-05 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of detecting transmissible spongiform encephalopathies |
US5814507A (en) * | 1996-05-24 | 1998-09-29 | Genentech, Inc. | κ/μ-like protein tyrosine phosphatase, PTP λ |
WO1998026293A1 (en) | 1996-12-12 | 1998-06-18 | Neuromark | Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms |
WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
DE19810721A1 (de) * | 1998-03-12 | 1999-10-14 | Werner Mueller | Anwendung der 14-3-3 Proteine sowie Verfahren zur schnellen Bestimmung der 14-3-3 Proteine als sensitive Biomarker für Pollution u. a. mit polychlorierten Biphenylen (PCBs) und (Xeno)Östrogenen |
WO1999051625A2 (en) | 1998-04-02 | 1999-10-14 | Rigel Pharmaceuticals, Inc. | Peptides causing formation of compact structures |
US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
WO2001066565A2 (en) | 2000-03-06 | 2001-09-13 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides |
US7056677B2 (en) * | 2000-03-17 | 2006-06-06 | Gemini Science, Inc. | Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them |
US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002252011A1 (en) * | 2001-02-21 | 2002-09-12 | Emory University | 14-3-3 binding molecules as sensitizers for anticancer therapies |
DE10131912A1 (de) | 2001-06-06 | 2002-12-19 | Werner E G Mueller | Verwendung von 14-3-3 Proteinen und Verfahren zu deren Bestimmung |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
US7172905B2 (en) | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
DE10159414A1 (de) | 2001-12-04 | 2003-06-18 | Infineon Technologies Ag | Bipolar-Transistor und Verfahren zum Herstellen desselben |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
GB0208331D0 (en) * | 2002-04-11 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Proteins |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
CN101412759A (zh) | 2003-01-10 | 2009-04-22 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
US7101962B2 (en) * | 2003-05-15 | 2006-09-05 | Bristol-Myers Squibb Company | Antibodies of the P2Y10 receptor useful in altering T lymphocyte function |
DE102004026815A1 (de) | 2003-06-03 | 2005-01-13 | Kabushiki Kaisha Tokai Rika Denki Seisakusho | Steuerung für ein Fernbedienungssystem |
WO2004113561A2 (en) | 2003-06-25 | 2004-12-29 | Queen's University At Kingston | Methods for diagnosing, monitoring, staging and treating heart failure |
JP4790624B2 (ja) | 2003-11-21 | 2011-10-12 | ジョンズ ホプキンス ユニバーシティ | 生体分子パーティションモチーフ及びそれらの使用 |
TWI281473B (en) | 2003-12-19 | 2007-05-21 | Ind Tech Res Inst | Biomarkers for liver diseases and method for using same |
EP2207033B1 (en) | 2004-04-15 | 2014-06-18 | University of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
US20070253961A1 (en) | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
US7786273B2 (en) | 2005-03-14 | 2010-08-31 | Medimmune, Llc | Macromolecules comprising a thioether cross-link |
GB2426581A (en) | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
PT2021792E (pt) * | 2006-05-09 | 2013-05-23 | Univ British Columbia | Marcadores proteicos dissolvidos para artrite |
US7939272B2 (en) | 2007-10-03 | 2011-05-10 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2009046267A1 (en) | 2007-10-05 | 2009-04-09 | University Of Virginia Patent Foundation | Protein-based biomarkers for abdominal aortic aneurysm |
US7919262B2 (en) | 2007-11-07 | 2011-04-05 | The Uab Research Foundation | 14-3-3 proteins for diagnosis of Parkinson's disease |
JP5781764B2 (ja) | 2007-11-27 | 2015-09-24 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 14−3−3η抗体、並びに関節炎の診断及び治療のためのその使用 |
US20100016173A1 (en) | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
US20120003225A1 (en) | 2008-05-09 | 2012-01-05 | Duke University | Autoantibodies in the detection and treatment of cancer |
US20130116150A1 (en) | 2010-07-09 | 2013-05-09 | Somalogic, Inc. | Lung Cancer Biomarkers and Uses Thereof |
AU2011312491B2 (en) | 2010-09-27 | 2015-06-04 | Somalogic, Inc. | Mesothelioma biomarkers and uses thereof |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-11-26 JP JP2010534331A patent/JP5781764B2/ja active Active
- 2008-11-26 EP EP17159003.7A patent/EP3192808A1/en not_active Ceased
- 2008-11-26 KR KR1020177027282A patent/KR20170116184A/ko not_active Application Discontinuation
- 2008-11-26 EP EP17159000.3A patent/EP3192807A1/en active Pending
- 2008-11-26 JP JP2010534332A patent/JP5615181B2/ja active Active
- 2008-11-26 US US12/745,235 patent/US9079947B2/en active Active
- 2008-11-26 US US12/745,229 patent/US20110027269A1/en not_active Abandoned
- 2008-11-26 CN CN200880125676.6A patent/CN101952313B/zh active Active
- 2008-11-26 WO PCT/CA2008/002094 patent/WO2009067811A1/en active Application Filing
- 2008-11-26 KR KR1020167029986A patent/KR101945394B1/ko active IP Right Grant
- 2008-11-26 KR KR1020107014288A patent/KR20100099221A/ko not_active Application Discontinuation
- 2008-11-26 KR KR1020187025773A patent/KR20180102215A/ko not_active Application Discontinuation
- 2008-11-26 CA CA2706479A patent/CA2706479C/en active Active
- 2008-11-26 AU AU2008329466A patent/AU2008329466B2/en active Active
- 2008-11-26 CN CN200880125674.7A patent/CN101925364B/zh active Active
- 2008-11-26 KR KR1020107014289A patent/KR20100100912A/ko not_active Application Discontinuation
- 2008-11-26 BR BRPI0819066-6A patent/BRPI0819066A2/pt not_active Application Discontinuation
- 2008-11-26 AU AU2008329529A patent/AU2008329529B2/en active Active
- 2008-11-26 BR BRPI0819063-1A patent/BRPI0819063A2/pt not_active Application Discontinuation
- 2008-11-26 EP EP08855660A patent/EP2222704A4/en not_active Ceased
- 2008-11-26 EP EP08853323A patent/EP2224955A4/en not_active Ceased
- 2008-11-26 WO PCT/CA2008/002154 patent/WO2009067820A1/en active Application Filing
- 2008-11-26 CA CA2706476A patent/CA2706476C/en active Active
- 2008-11-26 CN CN201711119889.5A patent/CN107880122A/zh active Pending
-
2010
- 2010-05-23 IL IL205907A patent/IL205907A0/en active IP Right Grant
- 2010-05-25 IL IL205948A patent/IL205948A/en active IP Right Grant
-
2011
- 2011-06-10 HK HK11105914.9A patent/HK1151728A1/zh unknown
-
2014
- 2014-05-28 JP JP2014109818A patent/JP6105516B2/ja active Active
- 2014-11-21 JP JP2014236075A patent/JP6054936B2/ja active Active
-
2015
- 2015-07-13 US US14/798,398 patent/US10995136B2/en active Active
- 2015-10-01 US US14/873,157 patent/US20160185842A1/en not_active Abandoned
-
2017
- 2017-03-02 JP JP2017039151A patent/JP2017149716A/ja active Pending
- 2017-08-27 IL IL254157A patent/IL254157B/en active IP Right Grant
-
2018
- 2018-10-05 HK HK18112716.8A patent/HK1253516A1/zh unknown
-
2019
- 2019-07-31 US US16/528,470 patent/US20200157195A1/en not_active Abandoned
-
2021
- 2021-05-03 US US17/306,913 patent/US20220106386A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253516A1 (zh) | 14-3-3η抗體及其用於診斷和治療關節炎的用途 | |
EP2078051A4 (en) | PROCESS FOR PRODUCTION OF POLYSILOXANES AND USE THEREOF | |
HK1208237A1 (zh) | 治療痛風的方法 | |
PL2293816T3 (pl) | Sposoby leczenia reumatoidalnego zapalenia stawów | |
ZA201003759B (en) | Antibodies against human nkg2d and uses thereof | |
EP2209625A4 (en) | ARTICLE AND MANUFACTURING METHOD THEREFOR | |
IL200610A0 (en) | Human monoclonal anti-ip-10 antibodies and uses thereof | |
IL193604A (en) | Use of human anti-22 @ il antibodies for @ preparation | |
AP2011005631A0 (en) | Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment. | |
PT2185719E (pt) | Anticorpos anti-rantes e processos para a sua utilização | |
ZA201002989B (en) | New antibodies specific of the beta-amyloid and their uses as diagnostic agents or drugs | |
IL184343A0 (en) | Gitr antibodies for the diagnosis of nsclc | |
EP2115458A4 (en) | METHOD FOR DIAGNOSIS OF HEALTH CONDITIONS FOR OVARIAL CARCINOMA AND THE RISK OF HEALTH CONDITIONS IN OVARIAL CARCINOMA | |
ZA201108057B (en) | 6'-sialyllactose salta and process for their synthesis and for the synthesis of other a-sialyloligosaccharides | |
EP2185718A4 (en) | HUMAN MONOCLONAL ANTIBODIES AND METHOD FOR THEIR MANUFACTURE | |
EP2048162A4 (en) | NEW MONOCLONAL ANTIBODY AND ITS USE | |
EP2156827A4 (en) | CATAPLASM AND PROCESS FOR PRODUCTION OF CATAPLASM | |
EP1992992A4 (en) | TONER AND MANUFACTURING METHOD THEREFOR | |
ZA201103941B (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
GB201020085D0 (en) | Methods and reagents for the treatment of arthritic disorders | |
EP1841457A4 (en) | TARGET APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | |
IL198479A0 (en) | Methods for screening for therapeutic molecules and use of the molecules therefrom | |
GB0602857D0 (en) | The treatment of sialorrhoea | |
AU2007905553A0 (en) | Process for the production of P2X7 antibodies and their use | |
SI2293816T1 (sl) | Postopki za zdravljenje revmatoidnega artritisa |